Fig. 5: Pharmacological mTOR and YAP inhibitors synergistically block tumor growth.
a SUM159 breast cancer cells were transplanted into the mammary fat pad of NSG mice and tumors allowed to develop for 27 days until reaching around 200 mm3 in tumor volume. Mice were split into four groups and subjected to vehicle (n = 6 mice), verteporfin (100 mg/kg) (n = 6 mice), torin1 (20 mg/kg) (n = 7 mice) and combination treatment (verteporfin/torin1, combo) (n = 7 mice) through daily intraperitoneal injections. Primary mammary tumor growth was assessed by measuring tumor volume. Data are represented as mean±SEM. p values are two-sided unpaired t test, *P < 0.05, or ***P < 0.001. b, c Percentage of cell viability in four TNBC cell lines (SUM159, MDA-MB231, SUM1315, SUM149) treated or not with torin1 or verteporfin for 3 days at the indicated doses, using Prestoblue staining. Data are represented as mean±SEM (n = 3 independent experiments for each cell line). d, e Four TNBC cell lines were treated with combinational drug matrix of verteporfin and torin1 at the indicated doses for 3 days. Cell viability was measured by PrestoBlue staining. Synergy scores and 3D surface plots of cell viability in four TNBC cell lines were quantified and analyzed with HSA, ZIP, and Bliss models using SynergyFinder (n = 3 independent experiments for each cell line). Source data are provided as a Source Data file.
